Bowel cancer test can predict its return

Some bowel cancer patients will be spared the ravaging effects of chemotherapy thanks to a breakthrough genetic test that can predict whether their cancer is likely to return.

The Mercy University Hospital in Cork is the first hospital in Europe to involve patients in a study using the test which will help doctors decide whether to include chemotherapy as part of their treatment.

“No one wants chemo and no doctor wants to prescribe it unless the benefits outweigh the risks,” said Dr Derek Power, consultant oncologist at the Mercy and lead researcher in the study.

While each test costs up to €3,000, substantial savings are made if the result indicates the cancer is unlikely to recur.

“The test is expensive but six months of chemotherapy costs the taxpayers 10 times more. So not only is it a great opportunity for patients, but it is more cost-effective in the long term,” Dr Power said.

The test, Oncotype Dx, is carried out after the patient’s tumour is removed and a sample from the tumour is sent by courier to the company that developed the test, Genomic Health Inc, in the US.

The result is emailed back within five to seven working days, with a report showing a recurrence score of between 0 and 100, calculated by analysing gene activity.

If the recurrence score is low, it means the chance of the cancer returning is low, making the need for chemotherapy unlikely.

“So instead of chemo and all the side-effects that go with it, all the patient may require is regular colonoscopies, CT scans, and blood tests,” Dr Power said.

The Mercy started using the test in September and it is also being used in Cork University Hospital, Kerry General, and the South Infirmary Victoria University Hospital.

Dr Power said they have reached an agreement with the company to pay a set price per month to carry out unlimited tests.

He said it was particularly welcome that the study was being conducted in Cork which has the highest incidence rate of bowel cancer in the country.

Bowel cancer is the second most common cancer in Ireland.

The test, approved and licenced in the US, is suitable for certain patients whose cancers are picked up at early stage 2 or 3.

Dr Power said they need to fundraise for the 18-month study. The Mercy Hospital Foundation is calling on companies, schools, and individuals to participate in Genes Day tomorrow “by planning a casual work day in jeans, a blue bake sale, a double denim fashion show, or a ‘jeanius’ quiz”.

To host your own Genes Day event, register at www.mercyfundraising.ie or call 021 4274076. Text Genes to 50300 to donate €4 to the foundation.


Lifestyle

Keep chomping on those carrots so your eyes will be in perfect working order for that prolonged annual gaze through the keyhole as Home of the Year returns for a sixth series next week.Home of the Year offers a good excuse for a bit of good-natured interiors voyeurism

They differ from the more prevalent oranges we eat because their flesh, and often the skin, is crimson or deep red in colour.Michelle Darmody: The best time of year to buy blood oranges

The annual Members Exhibition now underway at the Lavit Gallery in Cork features 92 works from 72 artists.The exhibition runs until March 7.Under the hammer: Your guide to upcoming auctions

There’s an oriental theme at the James Adam ‘At Home’ auction in Dublin, says Des O’SullivanAuctions: Sale full of eastern promise

More From The Irish Examiner